An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma

Phase I ◽

Dose Escalation ◽

Open Label ◽

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0838 ◽

2018 ◽

Vol 24 (6) ◽

pp. 747 ◽

Cited By ~ 14

Author(s):

Imane El Dika ◽

Ho Yeong Lim ◽

Wei Peng Yong ◽

Chia‐Chi Lin ◽

Jung‐Hwan Yoon ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Phase Ii ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Multicenter Phase ◽

Expansion Cohort

A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

Annals of Oncology ◽

10.1093/annonc/mdy282.080 ◽

2018 ◽

Vol 29 ◽

pp. viii234-viii235 ◽

Cited By ~ 1

Author(s):

A.-L. Cheng ◽

C.-J. Yen ◽

T. Okusaka ◽

M. Ikeda ◽

C.-H. Hsu ◽

...

Keyword(s):

Metastatic Hepatocellular Carcinoma

Monoclonal Antibody ◽

Phase I ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis

Journal of Hepatology ◽

10.1016/s0168-8278(15)31497-5 ◽

2015 ◽

Vol 62 ◽

pp. S849 ◽

Cited By ~ 2

Author(s):

B. Sangro ◽

A.B. El-Khoueiry ◽

T.S. Crocenzi ◽

T.H. Welling ◽

W. Feely ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Viral Hepatitis ◽

Dose Escalation ◽

Chronic Viral Hepatitis ◽

P1343 : Phase I dose-escalation study evaluating the safety and pharmacokinetics of oral artesunate in patients with advanced hepatocellular carcinoma (desparth trial)

Journal of Hepatology ◽

10.1016/s0168-8278(15)31522-1 ◽

2015 ◽

Vol 62 ◽

pp. S860

Author(s):

Y.-P. Vandewynckel ◽

K. Rombauts ◽

X. Verhelst ◽

L. Van Bortel ◽

B. De Spiegeleer ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4012 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4012-4012 ◽

Cited By ~ 20

Author(s):

Anthony B. El-Khoueiry ◽

Bruno Sangro ◽

Thomas Cheung Yau ◽

Todd S. Crocenzi ◽

Theodore Hobart Welling ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Dose Escalation ◽

Interim Analysis ◽

Faculty of 1000 evaluation for CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718099088.793483839 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Phase I ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment

European Journal of Cancer ◽

10.1016/s0959-8049(16)31272-2 ◽

2015 ◽

Vol 51 ◽

pp. S454

Author(s):

M. Ikeda ◽

T. Otsuka ◽

H. Ueno ◽

S. Mitsunaga ◽

R. Sugimoto ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Japanese Patients ◽

Dose Escalation Study ◽

Liver Impairment

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(12)61422-6 ◽

2012 ◽

Vol 56 ◽

pp. S555

Author(s):

S.M. Stemmer ◽

O. Benjaminov ◽

G. Medalia ◽

N.B. Ciuraru ◽

M.H. Silverman ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open‐Label, Dose‐Escalation Study

The Oncologist ◽

10.1634/theoncologist.2012-0211 ◽

2012 ◽

Vol 18 (1) ◽

pp. 25-26 ◽

Cited By ~ 54

Author(s):

Salomon M. Stemmer ◽

Ofer Benjaminov ◽

Gal Medalia ◽

Noab B. Ciuraru ◽

Michael H. Silverman ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

British Journal of Cancer ◽

10.1038/s41416-018-0051-8 ◽

2018 ◽

Vol 118 (9) ◽

pp. 1162-1168 ◽

Cited By ~ 5

Author(s):

D. H. Palmer ◽

Y. T. Ma ◽

M. Peck-Radosavljevic ◽

P. Ross ◽

J. Graham ◽

...

Keyword(s):

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase